In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
AION Labs launches AI startup to improve drug trials
Labiotech.eu
AION Labs has formed OMEC.AI, the labâs first startup approved by the Israel Innovation Authority. The new company will develop AI-powered solutions to analyze pre-clinical data and identify gaps in efficacy and safety to improve the probability of success of drug candidates in clinical trials.
AION Labs Launches AI Startup Addressing Drug Trial Improvement
AITHORITY
AION Labs, the first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced the formation of OMEC.AI, the labâs first startup approved by the Israel Innovation Authority. The new company will develop AI-powered solutions to analyze pre-clinical data and identify gaps in efficacy and safety to improve the success probability of drug candidates.
AION Labs Launches AI Startup Addressing Drug Trial Improvement
Mobile Health Times
OMEC.AI is the first company to be formed by Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X OMEC.AI will use advanced machine learning to improve probability of success for drug candidates in clinical trials.
BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology
PharmiWeb
Research team âEDCâ will study âExtrachromosomal DNA in Cancerâ. With this project, the two partners launch their ninth collaboration, seven of which have been in the field of oncology.
BioMedX Initiates New Oncology Research Project with Merck
Contract Pharma
BioMed X, a German independent research institute, has started its new research project âExtrachromosomal DNA in Cancerâ (EDC) in collaboration with Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and thereby trace back the mechanisms of ecDNA formation and function.
Merck Healthcare Business, BioMed X Begin New Research Project in Oncology
Medical Dialogues
Germany. BioMed X, a German independent research institute, has announced the start of its new research project titled ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with Healthcare Business of Merck KGaA, Darmstadt, Germany.
BioMed X Institute Enters New Collaboration with Merck
The Pharma Letter
German independent research institute BioMed X has announced the start of its new research project âExtrachromosomal DNA in Cancerâ (EDC) in collaboration with the Healthcare Business of Germanyâs Merck KGaA, Darmstadt. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and thereby trace back the mechanisms of ecDNA formation…
BioMed X Institute and Merck Start New Oncology Research Project
Labiotech.eu
BioMed X, a German independent research institute, has started a new research project âExtrachromosomal DNA in Cancerâ (EDC) in collaboration with the Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and trace back the mechanisms of ecDNA formation and function.
AION Labs, In Continued Partnership with BioMed X, Launches Fourth Global Call for Application: Prediction of Clinical Trial Outcome in Cancer Patient Populations
Mobile Health Times
AION Labs, Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), seeks global research talent for new startup focused on: âPrediction of Clinical Trial Outcome in Biomarker-Stratified Cancer Patient Populationsâ.
Global Call for Scientists and Inventors to Form New Startup
Labiotech.eu
AION Labs and German independent research institute BioMed X, announced today (June 29) the launch of the fourth global call for application to identify biomedical scientists and inventors to form a new startup in Israel. This fourth startup will focus on the development of an AI platform that optimizes the patient population for phase 3 clinical trial oncology studies.
BioMed X Ukraine Refugee Funding Program Included in the Science for Ukraine Database
#ScienceForUkraine
The BioMed X Institute, an independent research institute located in Heidelberg, Germany, is offering PhD positions in the field of Life Sciences (including pharmacology, bio-organic chemistry and physics) to early-career scientists from Ukraine.
Artificial Intelligence âBoot Campâ Aims to Accelerate Drug Discovery
Health Policy Watch
Together with its German partner BioMed X, AION Labs hosted 15 teams of computational biologists, AI researchers and biomedical scientists for a âboot campâ that aims to speed up the drug discovery process and lower costs â harnessing AI technologies in novel ways.
Joint Research Project to Examine Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging
LABMATE Online
A German independent research institute, BioMed X, announces today the start of its new research project âRegulatory T Cell Dysfunction in Autoimmunity and Inflammagingâ (TDA) in collaboration with Merck KGaA, Darmstadt, Germany.
Israel’s AION Labs Lanches Third Call For Proposals To Develop Antibody Therapies
nocamels
Israeli-headquartered, AION Labs, and German independent research institute, BioMed X, this week announced their third global call for biomedical scientists and interested investors to apply for a new AION Labs startup in Rehovot focused on âAI-enabled design and optimization of antibodies for targeted therapiesâ.